These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16520469)

  • 1. Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.
    Ann Intern Med; 2006 Mar; 144(5):I29. PubMed ID: 16520469
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
    Pignone M; Earnshaw S; Tice JA; Pletcher MJ
    Ann Intern Med; 2006 Mar; 144(5):326-36. PubMed ID: 16520473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of statins added to aspirin therapy.
    Chelmowski MK
    Ann Intern Med; 2006 Aug; 145(3):233; author reply 233-4. PubMed ID: 16880474
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
    Barry M; Heerey A
    Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
    Earnshaw SR; Scheiman J; Fendrick AM; McDade C; Pignone M
    Arch Intern Med; 2011 Feb; 171(3):218-25. PubMed ID: 21325111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin in primary prevention: sex and baseline risk matter.
    Algra A; Greving JP
    Lancet; 2009 May; 373(9678):1821-2. PubMed ID: 19482200
    [No Abstract]   [Full Text] [Related]  

  • 7. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
    Pignone M; Earnshaw S; Pletcher MJ; Tice JA
    Arch Intern Med; 2007 Feb; 167(3):290-5. PubMed ID: 17296886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
    Fidan D; Unal B; Critchley J; Capewell S
    QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
    Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
    Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
    Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
    Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.
    Galper BZ; Moran A; Coxson PG; Pletcher MJ; Heidenreich P; Lazar LD; Rodondi N; Wang YC; Goldman L
    Circulation; 2012 Jan; 125(2):260-70. PubMed ID: 22144567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
    Choudhry NK; Patrick AR; Antman EM; Avorn J; Shrank WH
    Circulation; 2008 Mar; 117(10):1261-8. PubMed ID: 18285564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing guidelines in primary care: can population impact measures help?
    Heller RF; Edwards R; McElduff P
    BMC Public Health; 2003 Jan; 3():7. PubMed ID: 12542840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.
    Hayden M; Pignone M; Phillips C; Mulrow C
    Ann Intern Med; 2002 Jan; 136(2):161-72. PubMed ID: 11790072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
    Walshe V; Nash A; Barry M
    Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
    Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
    Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].
    Kübler W
    Z Kardiol; 2005; 94 Suppl 3():III/92-9. PubMed ID: 16258799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.